Biocept (NASDAQ:BIOC) Research Coverage Started at StockNews.com

Analysts at StockNews.com started coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a research report issued on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, Maxim Group downgraded shares of Biocept from a “buy” rating to a “hold” rating in a research note on Friday, April 14th.

Get Biocept alerts:

Biocept Price Performance

BIOC stock opened at $2.00 on Wednesday. The company has a fifty day moving average price of $7.40 and a 200-day moving average price of $13.26. The company has a market capitalization of $1.18 million, a P/E ratio of -0.03 and a beta of 0.93. Biocept has a 52-week low of $1.99 and a 52-week high of $47.70. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.91 and a current ratio of 2.07.

Institutional Investors Weigh In On Biocept

A hedge fund recently raised its stake in Biocept stock. Renaissance Technologies LLC lifted its position in shares of Biocept, Inc. (NASDAQ:BIOC – Get Rating) by 50.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 175,500 shares of the medical research company’s stock after buying an additional 59,100 shares during the quarter. Renaissance Technologies LLC owned about 1.04% of Biocept worth $165,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

About Biocept

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Read More

• Get a free copy of the StockNews.com research report on Biocept (BIOC)
• Is American Airlines a Good Stock to Buy?
• High Dividend REITs: Are They an Ideal Way to Diversify?
• It Is Not Too Late To “Git” On Board With GitLab 
• Is Frontline’s 20% Dividend Too Good To Be True?
• Hospitality’s Rebound Has A Table At Cracker Barrel

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.